1
Rajinder Singh, Ankush Argade, Donald Payan, Susan Molineaux, Sacha J Holland, Jeffrey Clough, Holger Keim, Somasekhar Bhamidipati, Catherine Sylvain, Hui Li, Alexander B Rossi: Intermediates useful for making 2,4-pyrimidinediamine compounds. Rigel Pharmaceuticals, Dechert, June 13, 2006: US07060827 (128 worldwide citation)

The present invention provides 2,4-pyrimidinediamine compounds that inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in ...


2
Rajinder Singh, Ankush Argade, Donald Payan, Susan Molineaux, Sacha J Holland, Jeffrey Clough, Holger Keim, Somasekhar Bhamidipati, Catherine Sylvain, Hui Li, Alexander B Rossi: 2,4-pyrimidinediamine compounds and their uses. Rigel Pharmaceuticals, Foley & Lardner, James J Diehl, Brian D Griedel, February 19, 2008: US07332484 (79 worldwide citation)

The present invention provides 2,4-pyrimidinediamine compounds that inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in ...


3
Rajinder Singh, Ankush Argade, Donald Payan, Susan Molineaux, Sacha J Holland, Jeffrey Clough, Holger Keim, Somasekhar Bhamidipati, Catherine Sylvain, Hui Li, Alexander B Rossi: 2,4-pyrimidinediamine compounds and their uses. Rigel Pharmaceuticals, Foley & Lardner, James J Diehl, July 7, 2009: US07557210 (76 worldwide citation)

The present invention provides 2,4-pyrimidinediamine compounds that inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in ...


4
Rajinder Singh, Ankush Argade, Donald Payan, Susan Molineaux, Sacha J Holland, Jeffrey Clough, Holger Keim, Somasekhar Bhamidipati, Catherine Sylvain, Hui Li, Alexander B Rossi: 2,4-pyrimidinediamine compounds and their uses. Rigel Pharmaceuticals, Foley & Lardner, James J Diehl, Brian D Griedel, February 12, 2008: US07329671 (76 worldwide citation)

The present invention provides 2,4-pyrimidinediamine compounds that inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in ...


5
Rajinder Singh, Ankush Argade, Donald Payan, Susan Molineaux, Sacha J Holland, Jeffrey Clough, Holger Keim, Somasekhar Bhamidipati, Catherine Sylvain, Hui Li, Alexander B Rossi: 2,4-pyrimidinediamine compounds and their uses. Rigel Pharmaceuticals, Foley & Lardner, James J Diehl, Brian D Griedel, February 12, 2008: US07329672 (70 worldwide citation)

The present invention provides 2,4-pyrimidinediamine compounds that inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in ...


6
Rajinder Singh, Ankush Argade, Donald Payan, Susan Molineaux, Sacha J Holland, Jeffrey Clough, Holger Keim, Somasekhar Bhamidipati, Catherine Sylvain, Hui Li, Alexander B Rossi: 2,4-pyrimidinediamine compounds and their uses. Rigel Pharmaceuticals, Foley & Lardner, James J Diehl, February 3, 2009: US07485724 (67 worldwide citation)

The present invention provides 2,4-pyrimidinediamine compounds that inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in ...


7
Rajinder Singh, Ankush Argade, Donald Payan, Susan Molineaux, Sacha J Holland, Jeffrey Clough, Holger Keim, Somasekhar Bhamidipati, Catherine Sylvain, Hui Li, Alexander B Rossi: 2,4-Pyrimidinediamine compounds and their uses. Rogel Pharmaceuticals, Swiss Tanner P C, January 5, 2010: US07642351 (60 worldwide citation)

The present invention provides 2,4-pyrimidinediamine compounds that inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in ...


8
Rajinder Singh, Ankush Argade, Donald Payan, Susan Molineaux, Sacha J Holland, Jeffrey Clough, Holger Keim, Somasekhar Bhamidipati, Catherine Sylvain, Hui Li, Alexander B Rossi: 2,4-pyrimidinediamine compounds and their uses. Rigel Pharmaceuticals, Foley & Lardner, James J Diehl, March 3, 2009: US07498435 (52 worldwide citation)

The present invention provides 2,4-pyrimidinediamine compounds that inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in ...


9
Rajinder Singh, Ankush Argade, Donald Payan, Susan Molineaux, Sacha J Holland, Jeffrey Clough, Holger Keim, Somasekhar Bhamidipati, Catherine Sylvain, Hui Li, Alexander B Rossi: 5-Fluoro-4N-phenyl-4-pyrimidineamine compounds. Rigel Pharmaceuticals, Klarquist Sparkman, September 15, 2009: US07589200 (48 worldwide citation)

The present invention provides 2,4-pyrimidinediamine compounds that inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in ...


10
Rajinder Singh, Ankush Argade, Donald Payan, Susan Molineaux, Sacha J Holland, Jeffrey Clough, Holger Keim, Somasekhar Bhamidipati, Catherine Sylvain, Hui Li, Alexander B Rossi: 2,4-Pyrimidinediamine compounds and their uses. Rigel Pharmaceuticals, Foley & Lardner, James J Diehl, October 14, 2008: US07435814 (47 worldwide citation)

The present invention provides 2,4-pyrimidinediamine compounds that inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in ...